Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NewcelX ( (NCEL) ) has provided an update.
On January 5, 2026, NewcelX Ltd. announced the appointment of Dr. Julien Boisdron, a veteran diabetes specialist and current chief medical officer at a major Swiss large-cap pharmaceutical company, to its Scientific Advisory Board. With more than two decades of global leadership in diabetes care, including work in connected-care innovation, advanced insulin management and integration of therapeutic and digital solutions, Dr. Boisdron is expected to provide strategic guidance for IsletRx, NewcelX’s lead stem-cell-derived islet cell therapy program for insulin-dependent Type 1 Diabetes. His expertise will support the company’s translational strategy as IsletRx moves toward clinical trials, encompassing patient adoption, health-system integration and the design of future commercialization frameworks, bolstering NewcelX’s positioning in metabolic and regenerative medicine and potentially strengthening its path toward clinical and market readiness in diabetes treatment.
More about NewcelX
NewcelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, leveraging an integrated platform that combines advanced stem-cell technologies and neuroscience expertise. Headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel, the company focuses on scalable regenerative treatments for conditions such as ALS and Type 1 Diabetes, with Type 1 Diabetes as its primary clinical focus.
Average Trading Volume: 190,635
Technical Sentiment Signal: Sell
Current Market Cap: $9.53M
For detailed information about NCEL stock, go to TipRanks’ Stock Analysis page.